Name: Allergan PLC (NYSE:AGN) | Analysis of Revenues
Creator: Stock Analysis on Net

Analysis of Revenues

Allergan PLC, income statement, revenues

US$ in thousands

12 months ended:	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016	Dec 31, 2015
US Specialized Therapeutics	6,820,000)	6,920,300)	6,803,600)	5,811,700)	4,309,800)
US General Medicine	5,834,900)	5,322,900)	5,796,200)	5,923,900)	6,338,400)
International	3,402,000)	3,504,700)	3,319,500)	2,881,300)	2,187,300)
Anda Distribution	—)	—)	—)	—)	2,225,400)
Segment revenues	16,056,900)	15,747,900)	15,919,300)	14,616,900)	15,060,900)
Corporate revenues	32,000)	39,500)	21,400)	(46,300)	10,100)
Net revenues	16,088,900)	15,787,400)	15,940,700)	14,570,600)	15,071,000)

Download chart

Item	Description	The company
Net revenues	Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).	Allergan PLC net revenues decreased from 2017 to 2018 but then increased from 2018 to 2019 exceeding 2017 level.